Enlarged Prostate (BPH) vs. Prostate Cancer: Symptoms, Screening and PSA Decoded

Benign prostatic hyperplasia, or BPH, is non-cancerous growth of prostate tissue. The prostate surrounds the urethra just below the bladder. Enlargement can narrow the urinary passage and contribute to a slow stream, hesitancy, straining or a feeling that the bladder has not emptied.

Prostate cancer begins when cells grow abnormally. Having BPH does not mean it will become cancer, but benign enlargement and cancer may be present in the same person. A diagnosis of BPH therefore does not automatically explain every future symptom or test result.

Frequent urination, urgency and waking at night can have several causes, including bladder problems, medicines, infection and increased overnight urine production. The size of the prostate alone does not explain how troublesome symptoms are.

Early prostate cancer often causes no symptoms. Conversely, marked urinary symptoms do not automatically mean cancer. Your clinician will ask about the pattern, duration and impact on daily life, and may use urine tests, examination, a flow test or an ultrasound assessment of urine left in the bladder.

Prostate-specific antigen is a protein made by prostate cells. A blood test measures its level, but the result is not cancer-specific. Benign enlargement, inflammation or infection can raise it. Finasteride and dutasteride can lower PSA, so the clinician needs to know whether you take them.

There is no single PSA number that diagnoses cancer or guarantees its absence. Age, prostate size, previous results, examination and family history influence interpretation. Screening also has trade-offs: it can detect important disease but may lead to investigation or treatment of disease that would never have caused harm.

A result taken during an infection or soon after a urinary procedure may need to be reassessed at a more appropriate time. Tell the team about recent symptoms, treatment, catheterisation and all prostate medicines. Follow the laboratory’s preparation advice rather than attempting to change the result yourself.

If repeat testing is advised, ask when it should happen and who will review it. “Repeat later” should be a documented plan, not a reason to lose follow-up. A persistently concerning result needs an explanation and a next step.

A multiparametric MRI can identify suspicious areas and help decide whether a biopsy is appropriate. It can also guide where samples are taken. MRI estimates suspicion; it does not replace tissue diagnosis in every situation.

A reassuring MRI reduces concern but does not make cancer impossible. Further testing may still be advised if other risk factors remain concerning. If a biopsy is recommended, ask why, how it will be performed, and about bleeding, infection and temporary urinary difficulties. The biopsy result helps determine whether cancer is present and, if so, how aggressive it appears.

Bring earlier PSA results with their dates, any MRI report and images, urine test results and a current medicine list. Note whether close relatives have had prostate cancer and the age at diagnosis. Write down the urinary symptom that most affects your day.

You do not need to arrive knowing which test to request. A better goal is to leave understanding what is being investigated, how urgent the next step is and when the result will be reviewed.

• Could infection or medication be affecting my PSA?
• What is my individual reason for screening or further investigation?
• Would MRI change the decision about biopsy?
• If we monitor, when is the next review and what would trigger action?